Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag
Executive Summary
A recent report from law firm Gibson Dunn seems to show that the Trump administration, while aggressively pursuing opioid enforcement actions, slowed down enforcement in other areas during the first half of 2018. But important case-law developments continue.
You may also be interested in...
High Court Won’t Take Up Off-Label Case; Other FCA Issues On Docket
While the Supreme Court announced this week that it won’t hear a case related to off-label billings, other False Claims Act-related suits may still be on the docket.
Alere's $33.2m Settlement May Reflect Growing US Fed Focus On Dx
Abbott subsidiary Alere is paying $33.2m to settle allegations the company knowingly allowed hospitals to bill for tests performed using unreliable diagnostics marketed by the company. It's one of the first times that US DoJ has held a company responsible for false claims filed due to faulty test results.
US DoJ Memos May Hint At Enforcement Stepdown
The US Department of Justice has ordered its attorneys to ask for the dismissal of more whistleblower cases, and to avoid basing civil enforcement actions solely on guidance documents. Both could lead to fewer enforcement actions against device manufacturers.